62 products were found matching "K11219"!

TC JL 37 is an inhibitor of tyrosine kinase 2 (TYK2, Ki = 1. nM). It inhibits IL-12-induced phosphorylation of STAT4 in cells and IL-12- and IL-18-induced IFN-gamma production in isolated human peripheral blood mononuclear cells (PBMCs, EC50s = 224 and 168 nM, respectively). TC JL 37 (10-100 mg/kg) inhibits IL-12-...

RO495 is a tyrosine kinase 2 (TYK2) inhibitor.. Solulibility: DMSO: Soluble: = 10 mg/ml: Ethanol: Sparingly soluble: 1-10 mg/ml.

Tyrosine kinase 2 (TYK2) is a member of the JAK family of non-receptor tyrosine kinases that has a key role in cytokine signaling. It is composed of an N-terminal FERM homology domain, which mediates protein-protein interactions, a Src-homology 2 (SH2) domain, an autoinhibitory and catalytically inactive...

Description: SAR-20347 is an inhibitor of TYK2 and JAK1/2/3, with IC50 values of 0.6 nM, 23 nM, 26 nM, and 41 nM, respectively. Target: Tyrosine Kinases, JAK. Smiles: NC(=O)c1nc(oc1Nc1ccc(cc1)C(=O)N1CCOCC1)-c1c(F)cccc1Cl. References: Works MG, et al. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced...

Description: TYK2 Protein, Human, Recombinant (E. coli, His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 37.9 kDa and the accession number is P29597.

Description: TYK2 Protein, Human, Recombinant (His) is expressed in Baculovirus insect cells with N-10xHis tag. The predicted molecular weight is 34.4 kDa and the accession number is P29597.

Description: NDI-034858 (TAK-279) is a tyrosine kinase 2 (TYK2) inhibitor (Kd<200 pM) that targets the JH2 structural domain of Tyk2 for the treatment of autoimmune diseases caused by aberrant expression of IL12 and IL23. Target: IL Receptor, Tyrosine Kinases. Smiles:...

Janus kinase (JAK) is a family of intracellular, nonreceptor tyrosine kinases that play an important role in cytokine-mediated signaling. This family includes four protein kinases, Jak1, Jak2, Jak3 and Tyk2. Various studies have suggested that regulation of Jak activity should be a promising approach to combat...

Description: Deucravacitinib (BMS-986165) inhibits IL-12/23 and type I IFN pathways[1][2]. BMS-986165 is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases. Which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated...

PF-06826647 is an inhibitor of tyrosine kinase 2 (TYK2, IC50 = 15 nM). It is selective for TYK2 over JAK1, JAK2, and JAK3 (IC50s = 383, 74, and >10,000 nM, respectively). PF-06826647 inhibits IL-12-induced phosphorylation of STAT4 in isolated human whole blood (IC50 = 14 nM). In vivo, PF-06826647 (3-30 mg/kg, p.o.)...

Bayer 18 is a tyrosine kinase 2 (TYK2) inhibitor (IC50 = 18.7 nM). It is selective for TYK2 over JAK2, cyclin-dependent kinase 2 (Cdk2), and VEGFR2 (IC50s = 2,000, 1,790, and 3,520 nM, respectively).Formal Name:...

Description: Ropsacitinib (PF-06826647) is a selective TYK2 inhibitor, which binds to TYK2 catalytically active JH1 domain (IC50: 17 nM). Target: Tyrosine Kinases. Smiles: C(C#N)[C@@]1(C[C@H](C#N)C1)N2C=C(C=N2)C=3C=4N(C=C(N3)C=5C=NN(C)C5)N=CC4. References: Wrobleski ST, et al. Highly Selective Inhibition of Tyrosine...